Please assess the completion status of the following clinical trial:

Trial Title: LOTCOL Study: Local Treatment of Colo-rectal Liver Met

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically verified adenocarcinoma of colon or rectum~* Ambulatory with an ECOG performance status 0-2~* At least 18 years of age~* Non-resectable liver metastases~* Progressive disease on or within 4 months after 1.line chemotherapy for KRAS mutant or after 2.line chemotherapy in KRAS wild type patients~* 1-4 liver metastases with largest diameter of up to 6 cm on CT-scan~* Up to 20 lesions in liver with no more than 4 lesions larger than 4 cm~* The patients will start 2./3. line chemotherapy (KRAS mutant/KRAS wt)~* Laboratory values as the following:~  * ANC ³ 1.5 x 109/L~ * Platelets ³ 100 x 109/L~ * Hb ³ 9g/dL~ * Creatinine £ 2x upper limit of normal~ * Bilirubin \< 2.0x the upper limit of normal~ * ASAT and ALAT £ 5x the upper limit of normal~ * Albumin levels \> 30 g/L~ * INR\<1.3~* Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations~Exclusion Criteria:~* Previous treatment with 2. or 3. line chemotherapy (KRAS mutant/KRAS wt)~* History of prior metastatic disease the last 3 years~* History of CNS or bone metastases~* Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia~* Largest liver mets \>6 cm, more than 4 liver lesions \>4 cm~* Pulmonary mets\>3 cm~* Lymph node mets \>2.5 cm~* Chemotherapy/radiation therapy or major surgery within the last 4 weeks before start of treatment~* Any reason why, in the opinion of the investigator, the patient should not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cheomotherapy and local treatment (Type: EXPERIMENTAL): Standard chemotherapy + local treatment
- Cheomotherapy (Type: PLACEBO_COMPARATOR): Standard chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).